Buying Guides

Iclusig T315I: Who Is Iclusig For? (Ponatinib) | GLT

If you searched "iclusig t315i," you are asking about the one approved cancer drug that still works against the T315I mutation — the "gatekeeper" change that makes most other BCR-ABL inhibitors stop working. Iclusig (ponatinib) is that drug. This article answers the follow-up question who is Iclusig for: adults with T315I-positive chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), plus certain patients who have run out of other TKI options. GLT supplies the Iclusig (Ponatinib) 45mg tablets, the Takeda originator presentation, on a quote basis — with China-market pricing of the 15mg box at an indicative around $1,400.

What Is Iclusig (Ponatinib)?

Iclusig (ponatinib) is a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), an oral targeted therapy for two related blood cancers: chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Both diseases are driven by the BCR-ABL1 fusion gene, an abnormal kinase that sends a constant "keep dividing" signal into leukemia cells. TKIs like imatinib, dasatinib, nilotinib and bosutinib block that signal — but cancer cells can evolve mutations in the BCR-ABL gene that let them escape those earlier drugs.

Ponatinib was developed by ARIAD Pharmaceuticals (now part of Takeda) using structure-based drug design, specifically engineered to bind the BCR-ABL kinase even when it carries resistance mutations. The FDA first approved it in December 2012 under accelerated approval, with full approval following in 2016. In China it was approved in September 2024 under the Chinese brand name 英可欣, where it became the first and only third-generation TKI approved for both late-line CML and Ph+ ALL.

What Is the T315I Mutation?

The T315I mutation is the single most important resistance mutation in BCR-ABL-positive leukemia, and understanding it explains why Iclusig matters. In the BCR-ABL kinase, position 315 is the "gatekeeper" residue — a threonine (T) that sits at the entrance to the ATP-binding pocket where TKIs must dock. When that threonine is replaced by isoleucine (I), the mutation is written T315I. The larger isoleucine side chain physically blocks first- and second-generation TKIs from binding, which is why imatinib, dasatinib, nilotinib and bosutinib all lose activity against T315I-positive disease.

This is the clinical problem Iclusig was built to solve. Ponatinib was designed to bind the kinase without relying on the gatekeeper pocket, so it retains activity against native BCR-ABL and all known resistance mutations, including T315I. It remains the only approved TKI with meaningful activity against T315I — which is why a T315I test result so often leads a hematologist to Iclusig.

How T315I Is Detected — and the One Caveat

A T315I mutation is discovered through BCR-ABL1 kinase-domain mutation testing, usually ordered when a patient on TKI therapy shows rising BCR-ABL1 transcript levels, loss of response, or disease progression. Because the mutation dictates treatment selection, guidelines recommend mutation testing before switching therapy in resistant patients — the result is what tells a hematologist whether a T315I-capable drug like Iclusig is required.

One geographic caveat matters for accuracy. In the United States and Europe, Iclusig is the only approved TKI with T315I activity. In China, a second option exists: olverembatinib (耐立克), a China-developed third-generation TKI also active against T315I, approved for T315I-positive CML and Ph+ ALL. The choice between the two is made by the treating hematologist based on disease phase, cardiovascular risk profile, and drug availability — but globally, ponatinib remains the reference T315I inhibitor.

Who Is Iclusig For?

The question "who is Iclusig for" has a precise answer from the prescribing information. Iclusig is for adults with:

  • T315I-positive CML — in chronic phase, accelerated phase, or blast phase.
  • T315I-positive Ph+ ALL — as monotherapy.
  • Chronic-phase CML — in patients resistant or intolerant to at least two prior kinase inhibitors.
  • Accelerated-phase or blast-phase CML, or Ph+ ALL — for patients for whom no other kinase inhibitor is appropriate.
  • Newly diagnosed Ph+ ALL — in combination with chemotherapy (an accelerated-approval indication).

Two boundaries are equally important. Iclusig is not for newly diagnosed chronic-phase CML, where safer first-line options exist; and it is not for patients who can be well managed on earlier-generation TKIs. In practice, Iclusig is reserved for the two situations where it is genuinely indispensable: documented T315I mutation, and failure of at least two prior TKIs in chronic-phase disease.

Dosing: Start at 45mg, Step Down to 15mg

Iclusig comes as film-coated tablets in 15mg, 30mg and 45mg strengths (with a 10mg strength in some markets). The recommended starting dose for CML and Ph+ ALL is 45mg orally once daily, taken at the same time each day with or without food. The key modern refinement comes from the OPTIC trial: once a patient achieves a deep molecular response — BCR-ABL1 transcript of ≤1% on the International Scale — the dose is reduced to 15mg once daily for maintenance. This "response-guided dose reduction" preserves efficacy while substantially lowering the long-term risk of vascular events.

Dose adjustments for toxicity follow a step-down ladder: 45mg → 30mg → 15mg, or temporary interruption. A missed dose should not be doubled, and regular monitoring of blood counts, liver function, pancreatic enzymes, blood pressure and electrocardiograms is required throughout treatment.

Safety: The Boxed Warnings

Iclusig carries a boxed warning covering four serious risks, and this is the main reason it is used selectively rather than broadly:

  • Arterial occlusive events (AOEs) — including fatal heart attack, stroke, and severe peripheral vascular disease. These can occur even in patients under 50 and without classic cardiovascular risk factors.
  • Venous thromboembolic events (VTEs) — including deep-vein thrombosis and pulmonary embolism.
  • Heart failure — including fatal cases, requiring cardiac monitoring.
  • Hepatotoxicity — liver injury, liver failure and death, requiring regular liver-function monitoring.

The most common adverse reactions (≥20%) are rash, joint pain, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fever, nausea, peripheral edema and nosebleeds. Because of the vascular risks, the prescribing decision always weighs the benefit of controlling T315I-positive leukemia against these serious, potentially fatal side effects — under the supervision of a hematologist.

Iclusig Price and Where to Buy

Price is a real consideration for a therapy that may continue for months or years. The China-market originator presentation (英可欣) is listed at roughly RMB 10,000 per box of 15mg × 20 tablets — about $1,400 — and reimbursement access is still being finalized. GLT lists the Iclusig (Ponatinib) 45mg tablets on a quote basis for the Takeda originator. For patients seeking lower-cost options, generic ponatinib presentations from manufacturers such as Lucius and Everest are also available in 15mg and 45mg strengths, at substantially lower prices.

Whatever source you choose, ponatinib should be obtained only through a verifiable channel — a boxed-warning oncology medicine taken over months requires genuine, properly stored product. Because ponatinib is a prescription oncology medicine with a boxed warning, GLT follows an inquiry process rather than a self-service cart:

  1. Confirm the T315I status or treatment history with your hematologist.
  2. Send your inquiry via WhatsApp or email with the strength and quantity you need.
  3. Our team verifies availability and batch details, then arranges dispatch with appropriate storage.

For a broader look at sourcing China-approved oncology medicines, see our guide to sourcing China-sourced oncology medicines, and browse our other buying guides for related targeted therapies.

Questions or ready to order? Contact us on WhatsApp +86 15234153837 or email [email protected].

Frequently Asked Questions

What is the T315I mutation?

T315I is a resistance mutation in the BCR-ABL kinase where a threonine at position 315 is replaced by isoleucine. It physically blocks first- and second-generation TKIs from binding, making the leukemia resistant to those drugs.

Who is Iclusig for?

Iclusig is for adults with T315I-positive CML or Ph+ ALL, chronic-phase CML resistant to at least two prior TKIs, or accelerated/blast-phase CML and Ph+ ALL with no other suitable TKI. It is not for newly diagnosed chronic-phase CML.

Is Iclusig the only drug that works against T315I?

Yes — among BCR-ABL TKIs, Iclusig (ponatinib) is the only approved drug with meaningful activity against the T315I gatekeeper mutation. This is its defining clinical role.

What is the dose of Iclusig?

The recommended starting dose is 45mg once daily. After a deep molecular response (BCR-ABL1 ≤1% IS), the dose is reduced to 15mg once daily for maintenance under the OPTIC strategy.

What are the main risks of Iclusig?

Iclusig carries a boxed warning for arterial occlusive events, venous thromboembolism, heart failure, and hepatotoxicity. These can be serious or fatal and require close monitoring during treatment.

How much does Iclusig cost?

The China-market originator presentation is roughly RMB 10,000 per 15mg × 20-tablet box (about $1,400). Generic ponatinib is available at lower prices. Contact GLT for a current quote.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Iclusig (ponatinib) is a prescription oncology medicine with a boxed warning; always consult a qualified hematologist about diagnosis, dosing, and treatment. Prices are indicative and subject to confirmation at inquiry.

Hernexeos 60 mg Tablet: Zongertinib Buying Guide | GLT
Fruzaqla Buy Online: Fruquintinib (Elunate) Buying Guide | GLT